VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

CONy 2021 | EARLY 2: erenumab in the prevention of high-frequency episodic & chronic migraine in the real world

Piero Barbanti, MD, PhD, IRCCS San Raffaele Pisana, Rome, Italy, discusses the results of the EARLY 2 study evaluating the long-term effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in the real world. The multicenter, longitudinal study was conducted at 15 headache centers in Italy. Findings suggest that treatment with erenumab provides sustained effectiveness, safety, and tolerability in real-life patients with high-frequency episodic and chronic migraine ≥3 prior preventive treatment failures, which is a much more complex patient population than the one included in the controlled clinical trials. This interview was conducted during the virtual 2021 World Congress on Controversies in Neurology (CONy).

Disclosures

Advisory board, speaker bureau, investigational studies: Angelini, Assosalute, Bayer, Eli-Lilly, Lundbeck, Lusofarmaco, 1MED, MSD, Noema Pharma, Novartis, Teva, Visufarma, Zambon.